AstraZeneca's enhertu improved pCR in early-stage breast cancer

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care

Briefs: Tatva Chintan Pharma Chem and Shelter Pharma

Tatva Chintan Pharma Chem receives export order worth $35, 55,000

Senores Pharmaceuticals acquires ANDA for Topiramate HCl 25, 50, 100 and 200 mg tablets

Topiramate is indicated as a treatment of epilepsy and migraine

Alembic Pharmaceuticals posts Q4 FY25 consolidated PAT at Rs. 156.63 Cr

The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025

Innoxel Lifesciences completes USFDA inspection

This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence

OneSource Specialty Pharma reports consolidated Q4 FY25 PAT at Rs. 98.50 Cr

The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025

GPT Healthcare commissions new greenfield quaternary care hospital in Raipur

Biocon Biologics secures strong market coverage for Yesintek in US

Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025

RPG Life Sciences posts Q4 FY25 net profit at Rs. 117.35 Cr

RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025

AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease